Eurofins Scientific SE
OTCPK:ERFSF
Luxembourg / Healthcare / Life Sciences Tools & Services
Exchange Data
Hide this widget
Price
56.01 USD
Day change
1.68 (3.09%)
52-week range
44.61 - 68.45
Summary of Eurofins Scientific SE
Hide this widget
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. It provides services, s...
Latest Report
Jan 30, 2025Next Earnings
Apr 17, 2025
Price History
Chart Gallery
Hide this widget
1 Week
1 Month
3 Months
1 Year
5 Years
10 Years
3.90 (7.48%)
Data Explorer
Hide this widget
Search metric that you want to observe. Create your own widget, customise and rearrange metrics
| Metric Name | Value | Trend |
|---|---|---|
| Dividend Yield | 0.0% | |
| P/E Ratio | - | |
| Revenue | 7.201 B | |
| Net Income to Company | 420.1 M |
Peer Benchmarks
Hide this widget
Quote
Value
Size
Growth
Profit
| ERFS.F | Peers | Sector | |
|---|---|---|---|
Market Cap | 10.16 B | 12.672 B | 64.173 M |
Price % of 52 Week High | - | 70.6% | 62.0% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | 7.9% | 2.8% | -0.7% |
1 Year Price Total Return | -13.3% | -18.5% | -12.3% |
Beta (5 Year) | 0.71 | 1.03 | 0.64 |
In the News
Hide this widget
No data available
Fair Value
Hide this widget
Average
–
Upside
–
Uncertainty
–
Spread
–
Market Range
52 weeks
$45
$68
$56.01
Analyst Targets
0 analysts
-
Investing Models
0 models
-
Financial Health
Health Details
Hide this widget
Financial Health for Eurofins Scientific is determined by ranking the company on over 100 factors against companies in the Healthcare sector and operating in Developed economic markets.
12345
Good Performance
▼
▼
Financial Models for Eurofins Scientific SE
Model Gallery
Hide this widget
| DuPont ROE AnalysisView Updated 5 hours ago |
| 10Y Historical FinancialsView Updated 5 hours ago |
| 5Y Historical FinancialsView Updated 5 hours ago |
| CAPM WACC ModelView Updated 13 hours ago |
| Earnings Power ValueView Updated 17 hours ago |
Historical Financials
Full Financials
Hide this widget
| (USD in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 7,187 | 7,192 | 7,201 | 1,824 | 1,830 |
| Operating Income | 973 | 792 | 930 | 210 | 237 |
| Net Profit | 653 | 342 | 421 | 88 | 96 |
| Diluted EPS | 3.13 | 1.44 | 1.90 | 0.37 | 0.43 |
| EBITDA | 1,448 | 1,311 | 1,416 | 306 | 318 |
| Balance Sheet | |||||
| Cash & ST Invest. | 527 | 1,353 | 638 | 1,353 | 638 |
| Current Assets | 2,477 | 3,385 | 2,540 | 3,385 | 2,540 |
| Total Assets | 10,797 | 12,021 | 11,280 | 12,021 | 11,280 |
| Current Liabilities | 1,898 | 2,342 | 2,186 | 2,342 | 2,186 |
| Total Liabilities | 5,603 | 6,349 | 5,701 | 6,349 | 5,701 |
| Total Equity | 5,194 | 5,672 | 5,578 | 5,672 | 5,578 |
| Total Debt | 3,561 | 4,335 | 3,740 | 4,335 | 3,740 |
| Cash Flow Statement | |||||
| Cash Flow Operations | 1,217 | 1,124 | 1,366 | 378 | 408 |
| Cash From Investing | (916) | (752) | (877) | (195) | (188) |
| Cash From Financing | (333) | 457 | (1,129) | 115 | (260) |
| Free Cash Flow | 600 | 596 | 896 | 240 | 286 |
Analyst Notes
March 30, 2025
Hide this widget